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Mechanical loading plays a key role in the physiology of bone, allowing bone to func-
tionally adapt to its environment, however characterization of the signaling events linking
load to bone formation is incomplete. A screen for genes associated with mechanical
load-induced bone formation identiﬁed the glutamate transporter GLAST, implicating the
excitatory amino acid, glutamate, in themechanoresponse.When an osteogenic load (10N,
10Hz)was externally applied to the rat ulna, GLAST (EAAT1)mRNA,was signiﬁcantly down-
regulated in osteocytes in the loaded limb. Functional components from each stage of the
glutamate signaling pathway have since been identiﬁed within bone, including proteins
necessary for calcium-mediated glutamate exocytosis, receptors, transporters, and signal
propagation. Activation of ionotropic glutamate receptors has been shown to regulate the
phenotype of osteoblasts and osteoclasts in vitro and bone mass in vivo. Furthermore, glu-
tamatergic nerves have been identiﬁed in the vicinity of bone cells expressing glutamate
receptors in vivo. However, it is not yet known how a glutamate signaling event is initiated
in bone or its physiological signiﬁcance. This review will examine the role of the glutamate
signaling pathway in bone, with emphasis on the functions of glutamate transporters in
osteoblasts.
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THE GLUTAMATE SIGNALING PATHWAY
Glutamate is best known for its role as an excitatory signal-
ing molecule in the central nervous system (CNS) where it is
involved in learning and memory. Glutamate release from neu-
rons into the synaptic cleft is triggered by Ca2+ inﬂux through
voltage-sensitive calcium channels (VSCC), where it then acts
on a variety of receptors at the post-synaptic membrane, result-
ing in an inﬂux of Ca2+ into the post-synaptic neuron and
propagation of the depolarizing signal. Glutamate receptors can
be categorized into ionotropic and metabotropic (iGluR and
mGluR respectively). Ionotropic GluRs can be further classiﬁed
by sequence homology and agonist preference as DL-α-amino-3-
hydroxy-5-methylisoxazole-4-propionate (AMPA), kainate (KA),
and N-methyl-D-aspartate (NMDA), which are associated with
ion channels permeable to speciﬁc cations (Wisden and See-
burg, 1993; Hollmann and Heinemann, 1994). Metabotropic
GluRs are G-protein coupled and are categorized into three
functional groups based on their sensitivity to exogenous ago-
nists and intracellular signaling mechanisms; group I (mGluR1
and mGluR5), group II (mGluR2 and mGluR3), and group III
(mGluR4, mGluR6, mGluR7, and mGluR8; Masu et al., 1991;
Tanabe et al., 1992;Wisden and Seeburg, 1993). High-afﬁnity glu-
tamate transporters (excitatory amino acid transporters; EAATs)
at the pre-synaptic and post-synaptic membrane and neighbor-
ing glial cells terminate the signaling event by removing glutamate
from the synaptic cleft.
There is strong evidence to suggest that glutamate signaling
pathways are functional in several sites of the body besides the
CNS and bone (reviewed in Skerry and Genever, 2001; Hinoi
et al., 2004). Glutamate signaling mechanisms are able to detect
very fast stimulatory signals and self-modify, making them well-
suited for responding to mechanical signaling in bone (Skerry,
2002; Turner et al., 2002; Spencer and Genever, 2003; Bowe and
Skerry, 2005).
GLUTAMATE RELEASE
Osteoblasts express the functional components required for regu-
lated neuronal glutamate release including molecules involved in
synaptic vesicle packaging, targeting, and fusion (Bhangu et al.,
2001; Bhangu, 2003). Osteoblasts spontaneously release gluta-
mate in vitro (Genever and Skerry, 2001; Hinoi et al., 2002a)
and glutamate release by rat calvarial osteoblasts is increased
following depolarization with 50 mM KCl or activation of
iGluRs with AMPA (Hinoi et al., 2002a). The initiating stimu-
lus for glutamate release in osteoblasts remains unclear, though
Mason (2004) proposed that mechanical load may open stretch-
sensitive calcium channels in osteocytes to trigger glutamate
release by osteocytes and activate osteoblast receptors. Inter-
estingly, the intracellular glutamate concentration is regulated
during osteoblast differentiation through the action of glu-
tamine synthetase (GS), which converts glutamate to glutamine
(Olkku and Mahonen, 2008). During osteogenic differentiation
of rat mesenchymal stem cells (MSCs), GS activity declines
rapidly at the onset of mineralization increasing intracellular
glutamate concentrations (Olkku andMahonen, 2008; Zheng and
Quirion, 2009).
Mature osteoclasts, but not pre-osteoclasts, release glutamate
and bone degradation products from transcytotic vesicles follow-
ing depolarization with 50 mM KCl and this release is dependent
on extracellular Ca2+ (Morimoto et al., 2006).
www.frontiersin.org August 2012 | Volume 3 | Article 97 | 1
“fendo-03-00097” — 2012/8/2 — 18:21 — page 2 — #2
Brakspear and Mason Glutamate signaling in bone
GLUTAMATE RECEPTOR EXPRESSION AND FUNCTION
IONOTROPIC RECEPTORS
Various glutamate receptor subunits are expressed and functional
in bone cells (Table 1). Both glutamate and NMDA elicit sig-
niﬁcant increases in membrane currents in MG-63 and SaOS-2
osteoblast-like cells (Laketic-Ljubojevic et al., 1999) and in rab-
bit primary osteoclasts (Espinosa et al., 1999; Peet et al., 1999),
which can be inhibited by theNMDAreceptor antagonistMK-801.
NMDA receptors are also expressed and functional in primary
cultures of rat osteoblasts, with electrophysiological and phar-
macological characteristics similar to neuronal NMDA receptors
(Gu et al., 2002).
METABOTROPIC RECEPTORS
Transcripts have been detected for mGluR1b in rat femoral
osteoblasts (Gu and Publicover, 2000) and for mGluR4 and
mGluR8 in rat calvarial osteoblasts (Hinoi et al., 2001). Upon
exposure of rat femoral osteoblasts to 1S,3R-ACPD, an mGluR
agonist, elevated levels of intracellular Ca2+ were observed, indi-
cating functional group I mGluR expression (Gu and Publicover,
2000). The initial phase of this response was not dependent on
extracellular Ca2+ levels, reﬂecting mobilization of Ca2+ from
intracellular stores (Gu and Publicover, 2000). In rat calvarial
osteoblasts, a group III mGluR agonist signiﬁcantly inhibited
Table 1 | Reported transcript and protein expression of glutamatergic
signaling components in bone cells.
Osteoblast Osteoclast Osteocyte
NMDA
mRNA1−7 NMDAR1*,2A,
2B,2C,2D
NMDAR1*,2A,
2B,2C,2D
Protein1,4,5,6,8−10 NMDAR1*,2D* NMDAR1*,2A*,
2B*,2C*,2D*
NMDAR1*
AMPA
mRNA11 GluR3, 4
Protein8,9 GluR1,2 GluR1,2*,3*,4* GluR1*,2*
Kainate
mRNA12 KA1,2
Protein9 GluR5*,6*,7*
mGluR
mRNA2,3,13 mGluR1b,4,8 mGluR3,4,5,8
Protein13 mGluR8
EAAT
mRNA14−21 EAAT1*,2,3 EAAT2,4 EAAT1*,2
Protein14,16,19−21 EAAT1* EAAT4 EAAT1*
1Patton et al. (1998); 2Gu and Publicover (2000); 3Hinoi et al. (2001); 4Itzstein
et al. (2000); 5Itzstein et al. (2001); 6Hinoi et al. (2003); 7Merle et al. (2003);
8Chenu et al. (1998); 9Szczesniak et al. (2005); 10Ho et al. (2005); 11Hinoi et al.
(2002b); 12Hinoi et al. (2002a); 13Morimoto et al. (2006); 14Mason et al. (1997);
15Huggett et al. (2000); 16Kalariti et al. (2004); 17Takarada et al. (2004); 18Hinoi
et al. (2004); 19Kalariti et al. (2007); 20Hinoi et al. (2007); 21Takarada andYoneda
(2008).
*Denotes in vivo expression.
forskolin-induced cAMP accumulation in a manner that could
be prevented by co-treatment with a group III mGluR antagonist,
indicating functional group III mGluR expression (Hinoi et al.,
2001). Expression of mGluR6 has also been detected in rat bone
marrow stromal cells (Foreman et al., 2005). In these cells, treat-
ment with glutamate resulted in inhibition of Ca2+ inﬂux and
subsequent membrane hyperpolarization which was sensitive to
the group III mGluR antagonist (s)-MAP4, suggesting that acti-
vation of mGluR6 inhibits a Ca2+-permeable membrane channel
(Foreman et al., 2005).
Interestingly, NMDA currents in rat femoral osteoblasts that
were lost upon treatment with glutamate could be restored by
blockade of mGluRs, indicating that inhibitory cross talk occurs
between mGluRs and NMDA receptors in osteoblasts (Gu and
Publicover, 2000).
GLUTAMATE RECEPTOR REGULATION
Expression of iGluR subunits is regulated by mechanical load in
bone (Szczesniak et al., 2005). Long bones of adult rats subjected
to cyclic compressive load for four consecutive days displayed
a load-induced loss of immunoreactivity to various iGluR sub-
units in osteoclasts and bone lining cells (Szczesniak et al., 2005).
Furthermore, NMDA receptor expression was down-regulated in
osteoblasts in association with disuse-induced bone loss in rats
(Ho et al., 2005).
SECONDARY SIGNALING AND PHENOTYPIC EFFECTS
OSTEOBLASTS
The secondary signaling pathways following glutamate recep-
tor activation of osteoblasts have not been well-characterized,
although activation of receptor-associated protein kinases and
translocation of the transcription factor activator protein-1 (AP-1)
has been demonstrated (Taylor, 2002; Lin et al., 2008; Li et al.,
2011). Antagonists to NMDA receptors down-regulate the tran-
scription factor Runx2 and inhibit alkaline phosphatase activity
and osteocalcin expression in rat primary osteoblasts (Hinoi
et al., 2003; Ho et al., 2005). Consistent with this, more recent
studies have shown that the AMPA receptor antagonist 6-cyano-
7-nitroquinoxaline-2,3-dione (CNQX) and the NMDA receptor
antagonist MK-801 inhibit rat calvarial osteoblast activity and
mineralization, whilst the agonists, AMPA and NMDA, up-
regulate osteocalcin expression and mineralization of osteoblasts
in glutamate-free medium (Lin et al., 2008). In vivo evidence
also indicates an important role for glutamate signaling in bone
formation. Injection of AMPA locally into the tibia of young
rats increased bone volume in a manner that was prevented
by CNQX (Lin et al., 2008). Furthermore, mice treated with
the AMPA receptor antagonist NBQX or the NMDA receptor
antagonist AP5 by osmotic minipumps over 8 days, exhib-
ited altered bone structure (Burford et al., 2004). Trabecular
thickness was reduced in NBQX-treated mice whereas cortical
thickness at midshaft sites was reduced in AP5-treated mice
and increased in NBQX-treated mice (Burford et al., 2004).
This indicates different roles for NMDA and AMPA receptors
in the regulation of trabecular and cortical bone mass (Bur-
ford et al., 2004; Skerry, 2008). Finally, osteocalcin promoter-
driven knockout of NMDAR1 in mice causes stunted skeletons
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indicative of a role for glutamate signaling in skeletal development
(Skerry, 2008).
OSTEOCLASTS
Activation of NMDA receptors in osteoclasts inﬂuences cellular
phenotype in vitro. In co-cultures of mouse bone marrow leuko-
cytes and osteoblasts in which osteoclasts differentiate, MK-801
suppressed osteoclast differentiation and reduced resorption pit
formation in dentine (Peet et al., 1999). No signiﬁcant effects
of MK-801 upon mature osteoclast activity could be discerned
in this study (Peet et al., 1999), although others have reported
that MK-801 inhibits mature rabbit osteoclast activity (Chenu
et al., 1998; Itzstein et al., 2000) and promotes apoptosis, via
decreased NO production (Mentaverri et al., 2003). Glutamate
and NMDA receptor agonists induced nuclear translocation of
nuclear factor-kappaB (NF-κB) in osteoclast precursor cell lines,
and this was inhibited by MK-801 (Merle et al., 2003) indicat-
ing that glutamate-mediated activation of the NF-κB pathway is
involved in osteoclastogenesis.
GLUTAMATE TRANSPORTERS
HIGH-AFFINITY TRANSPORTERS
In the CNS, extracellular glutamate concentrations are tightly
controlled by high-afﬁnity, sodium-dependent glutamate trans-
porters. These transporters (EAATs) are classiﬁed into ﬁve sub-
types (EAAT1/GLAST, EAAT2/GLT-1, EAAT3/EAAC1, EAAT4,
and EAAT5; Kanai and Hediger, 1992; Pines et al., 1992; Storck
et al., 1992; Tanaka, 1993; Arriza et al., 1994, 1997; Fairman et al.,
1995). Several splice variants of EAATs 1–3 have been reported,
which have altered function and expression proﬁles (Lin et al.,
1998; Nagai et al., 1998; Matsumoto et al., 1999; Meyer et al., 1999;
Huggett et al., 2000; Vallejo-Illarramendi et al., 2005). Each EAAT
subtype displays heterologous spatial and cellular expression pro-
ﬁles (Danbolt, 2001) indicating a complex and ﬁnely tuned control
over extracellular glutamate levels.
Excitatory amino acid transporters transport glutamate against
its concentration gradient. Three sodium ions and one proton are
co-transported with glutamate and one potassium ion is counter-
transported leading to a net positive charge moving into the
cell (Zerangue and Kavanaugh, 1996). EAATs also function as
ion channels whereby sodium-dependent glutamate binding ini-
tiates an uncoupled anion conductance (Seal and Amara, 1999;
Slotboom et al., 2001) that is physiologically measurable (Billups
et al., 1996; Eliasof and Jahr, 1996). The role of the anion con-
ductance is unclear, though it has been suggested that it may
compensate for the membrane potential changes due to elec-
trogenic glutamate uptake (Billups et al., 1996; Eliasof and Jahr,
1996). The chloride conductance may also modulate glutamate
receptor activity or operate like a receptor, activating intracellu-
lar signaling cascades in response to glutamate binding (Danbolt,
2001; Mason and Huggett, 2002). In addition to transport and ion
channel activities, protein–protein interactions with both N- and
C-terminal domains of the EAATs suggest a potential receptor-like
function for the EAATs. Interactions with the actin cytoskele-
ton and the mitogen-activated protein kinase (MAPK) cascade
have been reported (Abe and Saito, 2001; Marie et al., 2002;
Sullivan et al., 2007).
EAAT EXPRESSION AND FUNCTION IN BONE
GLAST and GLT-1 are expressed in osteoblasts and osteocytes
in vivo (Mason et al., 1997) and EAAT3 has been detected in rat
primary osteoblasts in vitro (Takarada et al., 2004; Table 1). In
contrast, EAATs 2 and 4 appear to be the predominant EAATs
in osteoclasts (Hinoi et al., 2007; Takarada and Yoneda, 2008).
GLAST-1a, a splice variant lacking domains important for anion
conductance is also expressed in bone in vivo (Huggett et al., 2000).
Despite EAATs being the ﬁrst component of glutamatergic
signaling to be identiﬁed in bone, the majority of glutamate sig-
naling research within bone has focused on the activity of the
glutamate receptors. It has been hypothesized that the EAATs
might play a direct role in regulating the phenotype of bone cells
via their various activities; glutamate uptake, glutamate release,
glutamate-gated ion channel, or activation of intracellular sig-
naling pathways (Mason, 2004). This has been supported by
studies reporting that the EAAT inhibitor t-PDC prevents bone
formation of calvarial osteoblasts in vitro (Taylor, 2002) and our
data showing that pharmacological EAAT inhibition can inﬂu-
ence the bone-forming phenotype of osteoblast-like cells in vitro
(Brakspear et al., 2009).
In vivo evidence that GLAST is expressed in bone where it is
mechanically regulated in osteocytes and osteoblasts (Mason et al.,
1997) indicates that the transport system is physiologically rele-
vant (Mason et al., 1997). Although, knockout of GLAST has been
reported to have no affect on bone length (Gray et al., 2001), the
role of GLAST in bone remodeling and responses to load remains
unknown (Chenu et al., 2001; Skerry et al., 2001).
We have observed that EAAT subtypes are differentially
expressed across MG-63, SaOS-2, and human primary osteo-
blasts – EAAT1 mRNA is expressed at high levels com-
pared to EAAT3 while the expression of EAAT2 is low and
this varies with each cell type (Brakspear et al., 2009). This
complicates interpretation of the effects of EAAT inhibition
since uptake kinetics, Cl− conductance, post-translational
regulation and protein–protein interactions (reviewed in
Danbolt, 2001) vary across the EAAT subtypes. The localization
of different EAAT subtypes within the cell is tightly regulated
(reviewed in Danbolt, 2001; Amara and Fontana, 2002). EAAT
localization adjacent to speciﬁc glutamate receptor subtypes will
modulate the glutamate available for receptor activation, inﬂuenc-
ing intracellular signaling events. For example glutamate uptake
through EAAT4 limits mGluR activation in Purkinje neurons in
the cerebellum (Wadiche and Jahr, 2005) and GLAST restricts
the activation of mGluRs in hippocampal neurons (Huang et al.,
2004). The intracellular localization of EAATs are differentially
regulated by extracellular glutamate concentrations in osteoblasts
(Huggett et al., 2002), consistent with the notion that EAATs
may exhibit similar mechanisms of regulating glutamate receptor
activation in bone cells.
CYSTINE/GLUTAMATE ANTIPORTERS
Cystine/glutamate antiporters are sodium-independent, chloride-
dependent high-afﬁnity glutamate transporters (Bannai, 1986;
Sato et al., 1999). The transporter is a heterodimer of the CD38
heavy chain (also called 4F2hc) and the X−C (referred to as xCT)
light chain. Cystine (the dimeric form of cysteine) is necessary
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for the generation of the tripeptide antioxidant glutathione
(γ-Glu-Cys-Gly; GSH; reviewed in Cooper and Kristal, 1997;
Dringen, 2000). The cystine/glutamate antiporter is expressed and
functionally required for the differentiation of pre-osteoblasts,
pre-osteoclastic RAW264.7 cells, and primary osteoclasts from
bone marrow precursor cells (Hinoi et al., 2007; Takarada-Iemata
et al., 2010). Differentiation was inhibited by high glutamate con-
centrations (over 500 μM) in a manner that was sensitive to
inhibitors of the antiporter. High concentrations of extracellu-
lar glutamate are likely to result in cystine being released from
the cell, thus reducing intracellular cystine available to generate
GSH. The cystine/glutamate antiporter is also expressed in undif-
ferentiated MC3T3-E1 osteoblast-like cells where it suppresses
proliferation, without inducing cell death, following treatment
with exogenous glutamate in association with decreased levels of
intracellular GSH (Uno et al., 2007). Interestingly, recent ﬁndings
have indicated that the activity of the antiporter down-regulates
Runx2 expression and alkaline phosphatase activity inMC3T3-E1
cells and mouse calvarial osteoblasts under differentiating condi-
tions (Uno et al., 2011) suggesting that the role of the antiporter
in bone cells may be maturation-stage speciﬁc. The intracellular
concentration of glutamate increases at the onset of mineral-
ization (Olkku and Mahonen, 2008; Zheng and Quirion, 2009),
which may explain the stage-speciﬁc inhibitory activity of the
antiporter.
VESICULAR GLUTAMATE TRANSPORTERS
Vesicular glutamate transporters (VGLUTs) package glutamate
into vesicles for exocytic release. Expression of VGLUT1, but not
VGLUT2, has been detected in rat calvarial osteoblasts (Hinoi
et al., 2002a) and glutamate release from these cells was Ca2+-
dependent and sensitive to AMPA GluR antagonists (Hinoi et al.,
2002a). VGLUT1 is also expressed by mature osteoclasts and
is thought to accumulate glutamate into transcytotic vesicles
for release, with bone degradation products, upon stimula-
tion with 50 mM KCl or ATP in a Ca2+-dependent manner
(Morimoto et al., 2006). Glutamate released from osteoclasts by
transcytosis may be autoregulatory, since agonists to osteoclas-
tic mGluR8 inhibits secretion of glutamate and bone degradation
products whereas mGluR8 antagonists stimulate bone resorption
(Morimoto et al., 2006).
PATHOLOGICAL IMPLICATIONS OF GLUTAMATE SIGNALING
IN OSTEOBLASTS
Glutamatergic signaling was ﬁrst discovered in bone in a screen
to identify genes associated with mechanically induced bone
formation (Mason et al., 1997). Since then there has been sub-
stantial evidence that glutamate signaling canmodulate osteoblast
differentiation and activity, via two opposing mechanisms
(Figure 1A).
Proliferation and osteoblast differentiation of MC3T3-E1 and
mesenchymal C3H10T1/2 stem cells infected with Runx2 aden-
ovirus were prevented by high concentrations of glutamate which
inhibit the cystine/glutamate antiporter and reduce GSH levels
(Uno et al., 2007; Takarada-Iemata et al., 2010), whereas gluta-
mate activation of the NMDA receptor increases Runx2 and ALP
activity of rat calvarial osteoblasts if added after the proliferative
stage of maturation (Hinoi et al., 2003). These data suggest that
high concentrations of glutamate inhibit pre-osteoblast differen-
tiation in association with GSH depletion, but that activation of
speciﬁc glutamate receptors increases differentiation and bone-
forming activity of committed osteoblasts. Indeed, overexpression
of the cystine/glutamate antiporter xCT subunit in differentiating
MC3T3-E1 cells negatively regulated Runx2 expression in these
cells, indicating an altered role for the antiporter, and thus the
effects of extracellular glutamate on this antiporter, in commit-
ted osteoblasts (Uno et al., 2011). These different mechanisms
may reﬂect changes in the expression and activity of glutamate
signaling components during maturation of osteoblasts, or the
inﬂuence of different extracellular glutamate concentrations, i.e.,
pathophysiological concentrations inhibit the cystine/glutamate
antiporter whereas physiological concentrations activate gluta-
mate receptors. Intriguingly, synovial ﬂuid glutamate concen-
trations are greatly increased in osteoarthritis and rheumatoid
arthritis (RA; McNearney et al., 2004) where major disruption
in bone remodeling occurs. Elucidation of the inﬂuence of
extracellular glutamate concentrations, maturation-stage, and the
diversity of subunits and splice variants that contribute to each
receptor/transporter is essential for progress toward therapeutic
targeting of glutamatergic in the treatment of bone and joint
disorders.
INTERACTIONS WITH OTHER SIGNALS
Evidence from the CNS suggests interplay may exist between glu-
tamate and other signaling pathways that are important in bone
such as insulin-like growth factor (IGF), adenosine, and calcium
(Gama et al., 2001; Ferre et al., 2002; Garcia-Galloway et al., 2003;
Domenici et al., 2004; Ciruela et al., 2006; Zheng and Quirion,
2009). IGF has been implicated inmechanical load-induced osteo-
genesis, while adenosine and calcium receptors can inﬂuence bone
formation (Dvorak and Riccardi, 2004; Dvorak et al., 2004; Evans
et al., 2006). Activation of PLC by parathyroid hormone (PTH) in
rat femoral osteoblasts prevented calcium inﬂux through NMDA
receptors suggesting interplay between these two pathways in bone
(Gu and Publicover, 2000). Furthermore, the canonical Wnt sig-
naling pathway negatively regulates the activity of GS in MG-63
cells, thus increasing the intracellular glutamate concentration
(Olkku and Mahonen, 2008).
SUMMARY
A physiological role for glutamate in the regulation of bone mass
has been highlighted by transgenic models lacking components of
the signaling pathway which display altered bone structure. Fur-
thermore, glutamate receptor activation regulates osteoblast and
osteoclast differentiation and activity, and osteogenic mechanical
load regulates expression of GLAST and glutamate receptors in
bone in vivo (Mason et al., 1997; Ho et al., 2005; Szczesniak et al.,
2005). The inﬂuence of glutamate in bone depends upon the cell
type, the differentiation stage and the extracellular glutamate con-
centration (Figure 1B). As in the CNS, glutamatergic signaling
in bone is highly complex involving multiple components with
different roles in various cell types.
High glutamate concentrations in synovial ﬂuids of RApatients
activate nerves within the joint to cause pain. Since, many joint
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FIGURE 1 | Hypothetical model of glutamate signaling in (A) osteoblasts
and (B) bone. (A) Osteoblasts release glutamate to activate glutamate
receptors in an autocrine and paracrine manner and express functional
ionotropic and metabotropic glutamate receptors. iGluR activation leads to
glutamate release and increased Runx2 activity, regulating osteocalcin
expression, ALP activity and mineralization (Hinoi et al., 2002c, 2003; Ho
et al., 2005). mGluR activation inhibits NMDA receptor signals in osteoblasts
via PLC activated pathways (Gu and Publicover, 2000). High extracellular
[glutamate] inhibits the cystine/glutamate antiporter, suppressing proliferation
and reducing Runx2 activity due to depletion of GSH (Uno et al., 2007;
Takarada-Iemata et al., 2010). EAATs transport glutamate into osteoblasts,
modulating localized receptor responses, but also activating a chloride ﬂux,
which may function as a voltage clamp, act directly as a receptor, or modulate
GluR activation by regulating ion inﬂux (Danbolt, 2001; Huggett et al., 2002).
Various proteins interact with the intracellular domains of EAAT1 and
glutamate transport through EAATs activates MAPK (Abe and Saito, 2001).
(B) Opening of stretch- and voltage-sensitive calcium channels (SSCC, VSCC)
in osteocytes in response to mechanical load increases intracellular
[Ca2+] to induce glutamate release into junctions with neighboring
osteocytes (Mason, 2004). Down-regulation of EAAT1 in mechanically
loaded osteocytes (Mason et al., 1997) would increase extracellular
[glutamate] which could regulate osteoblast differentiation and activity as
described above. Osteoclasts are also likely to be regulated by released
glutamate. Osteoclasts express EAATs 2 and 4 (Hinoi et al., 2007; Takarada
andYoneda, 2008) and NMDA receptor activation promotes NF-κB stimulated
osteoclast differentiation (Peet et al., 1999; Merle et al., 2003) and increases
mature osteoclast activity (Chenu et al., 1998; Itzstein et al., 2000; Mentaverri
et al., 2003). Mature osteoclasts release glutamate in conjunction with bone
degradation products, which can act on autoregulatory mGluRs, preventing
further glutamate release (Morimoto et al., 2006). Therefore, glutamate
signals may contribute to mechanical cues and coupling of bone remodeling.
PLC, phospholipase C; DAG, diacylglycerol; cAMP, cyclic adenosine
monophosphate; PKC, protein kinase C; IP3, inositol triphosphate; ALP,
alkaline phosphatase; ROS, reactive oxygen species; MAPK,
mitogen-activated protein kinase; EAAT, excitatory amino acid transporter;
GSH, glutathione.
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tissues express functional glutamate transporters and receptors,
and release this signal, the role of glutamatergic signaling in coor-
dinating joint loading to symptoms of pain, inﬂammation and
joint destruction is of great interest.
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